Brassicasterol inhibits hepatitis B virus-associated hepatocellular carcinoma development via suppression of AKT signaling pathway

BACKGROUND: Hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) does not respond well to current treatment options like sorafenib, and there is an urgent need for developing therapeutical strategies for HBV + HCC. Brassicasterol has previously shown anti-cancer and anti-viral activitie...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Jindi, Wu, Jiancheng, Pang, Shuijiao, Wang, Feifei, Yu, Xin, Zhang, Shouhua, Zeng, Junquan, Yan, Jinlong, Lian, Jianping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116783/
https://www.ncbi.nlm.nih.gov/pubmed/37081537
http://dx.doi.org/10.1186/s13027-023-00502-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116783/
https://www.ncbi.nlm.nih.gov/pubmed/37081537
http://dx.doi.org/10.1186/s13027-023-00502-1

Ejemplares similares